These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

718 related articles for article (PubMed ID: 24022639)

  • 41. Vaccines against human papillomavirus and cervical cancer: promises and challenges.
    Mahdavi A; Monk BJ
    Oncologist; 2005 Aug; 10(7):528-38. PubMed ID: 16079320
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Decreasing risk: impact of HPV vaccination on outcomes.
    Hymel PA
    Am J Manag Care; 2006 Dec; 12(17 Suppl):S473-83. PubMed ID: 17203991
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Cervical cancer prevention: the impact of HPV vaccination].
    Monsonégo J
    Gynecol Obstet Fertil; 2006 Mar; 34(3):189-201. PubMed ID: 16529969
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prospects and prejudices of human papillomavirus vaccines in India.
    Das BC; Hussain S; Nasare V; Bharadwaj M
    Vaccine; 2008 May; 26(22):2669-79. PubMed ID: 18455843
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluating the impact of human papillomavirus vaccines.
    Chang Y; Brewer NT; Rinas AC; Schmitt K; Smith JS
    Vaccine; 2009 Jul; 27(32):4355-62. PubMed ID: 19515467
    [TBL] [Abstract][Full Text] [Related]  

  • 46. HPV vaccine cross-protection: Highlights on additional clinical benefit.
    De Vincenzo R; Ricci C; Conte C; Scambia G
    Gynecol Oncol; 2013 Sep; 130(3):642-51. PubMed ID: 23747835
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Introducing human papillomavirus vaccines - questions remain.
    Paavonen J; Lehtinen M
    Ann Med; 2008; 40(3):162-6. PubMed ID: 18382882
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Correlating immunity with protection for HPV infection.
    Frazer I
    Int J Infect Dis; 2007 Nov; 11 Suppl 2():S10-6. PubMed ID: 18162240
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix.
    Schwarz TF
    Adv Ther; 2009 Nov; 26(11):983-98. PubMed ID: 20024678
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prevention strategies against the human papillomavirus: the effectiveness of vaccination.
    Stanley M
    Gynecol Oncol; 2007 Nov; 107(2 Suppl 1):S19-23. PubMed ID: 17938013
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Human papillomavirus vaccines for the prevention and treatment of cervical cancer.
    Tomson TT; Roden RB; Wu TC
    Curr Opin Investig Drugs; 2004 Dec; 5(12):1247-61. PubMed ID: 15648945
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Vaccination against human papillomavirus. Implementation and efficacy against cervical cancer control].
    Bégué P; Henrion R; Blanc B; Girard M; Sancho-Garnier H
    Bull Acad Natl Med; 2007 Dec; 191(9):1805-16; discussion 1816-7. PubMed ID: 18663976
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Human papillomavirus vaccines].
    Brun JL
    J Gynecol Obstet Biol Reprod (Paris); 2008 Feb; 37 Suppl 1():S155-66. PubMed ID: 18187268
    [TBL] [Abstract][Full Text] [Related]  

  • 54. HPV vaccines: preclinical development.
    Gissmann L
    Arch Med Res; 2009 Aug; 40(6):466-70. PubMed ID: 19853186
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Advantages and disadvantages of current prophylactic vaccines against HPV.
    Madrid-Marina V; Torres-Poveda K; López-Toledo G; García-Carrancá A
    Arch Med Res; 2009 Aug; 40(6):471-7. PubMed ID: 19853187
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Vaccination against human papillomavirus for the prevention of cervical cancer].
    Quint WG; ter Harmsel WA; van Doorn LJ
    Ned Tijdschr Geneeskd; 2006 Jun; 150(25):1380-4. PubMed ID: 16841585
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Central and Eastern Europe.
    Poljak M; Seme K; Maver PJ; Kocjan BJ; Cuschieri KS; Rogovskaya SI; Arbyn M; Syrjänen S
    Vaccine; 2013 Dec; 31 Suppl 7():H59-70. PubMed ID: 24332298
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Human papillomavirus vaccine and cervical cancer prevention: practice and policy implications for pharmacists.
    McIntosh J; Sturpe DA; Khanna N
    J Am Pharm Assoc (2003); 2008; 48(1):e1-13; quiz e14-7. PubMed ID: 18192123
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Anti-papillomavirus vaccines and prevention of cervical cancer: progress and prospects].
    Hantz S; Alain S; Denis F
    Presse Med; 2005 Jun; 34(10):745-53. PubMed ID: 16026130
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oral immunization with bacteriophage MS2-L2 VLPs protects against oral and genital infection with multiple HPV types associated with head & neck cancers and cervical cancer.
    Zhai L; Yadav R; Kunda NK; Anderson D; Bruckner E; Miller EK; Basu R; Muttil P; Tumban E
    Antiviral Res; 2019 Jun; 166():56-65. PubMed ID: 30926288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.